IGM Biosciences, Inc.(IGMS)

$1.27—

Chart

IGM Biosciences, Inc.(IGMS)

NASDAQ

$1.27—

Chart Studio

IGMS(IGMS)

IGMS

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Analyst Sentiment

Wall St. Consensus

Hold

17 analysts·Moderate coverage

Score

8 Buy (47%)9 Hold (53%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

847%

Hold

953%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$1.50

+18.1%

Consensus

$21.00

+1553.5%

Bull

$31.00

+2340.9%

12-Month Target Range17 analysts

$1.50$21.00$31.00

Current $1.27Consensus

Current Price

$1.27

Upside to Consensus

$19.73

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+2.88%

EPS—

FY2028

Rev-65.23%

EPS—

FY2029

Rev+25.36%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E
Revenue Avg	$14M	$14M	$5M	$6M
Low	$14M	$14M	$5M	$6M
High	$14M	$14M	$5M	$6M
EBITDA Avg	$-3M	$-3M	$-969,999	$-1M
Low	$-3M	$-3M	$-969,999	$-1M
High	$-3M	$-3M	$-969,999	$-1M
EBIT Avg	$-3M	$-3M	$-969,999	$-1M
Low	$-3M	$-3M	$-969,999	$-1M
High	$-3M	$-3M	$-969,999	$-1M
Net Income Avg	$-85M	$-98M	$-31M	$-22M
Low	$-85M	$-98M	$-31M	$-22M
High	$-85M	$-98M	$-31M	$-22M
EPS Avg	$-1.40	$-1.62	$-0.51	$-0.37
Low	$-1.40	$-1.62	$-0.51	$-0.37
High	$-1.40	$-1.62	$-0.51	$-0.37
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$6M	$6M	$6M	$6M	$6M	$6M
Low	$6M	$6M	$6M	$6M	$6M	$6M
High	$6M	$6M	$6M	$6M	$6M	$6M
EBITDA Avg	$-1M	$-1M	$-1M	$-1M	$-1M	$-1M
Low	$-1M	$-1M	$-1M	$-1M	$-1M	$-1M
High	$-1M	$-1M	$-1M	$-1M	$-1M	$-1M
EBIT Avg	$-1M	$-1M	$-1M	$-1M	$-1M	$-1M
Low	$-1M	$-1M	$-1M	$-1M	$-1M	$-1M
High	$-1M	$-1M	$-1M	$-1M	$-1M	$-1M
Net Income Avg	$-36M	$-38M	$-39M	$-41M	$-43M	$-45M
Low	$-36M	$-38M	$-39M	$-41M	$-43M	$-45M
High	$-36M	$-38M	$-39M	$-41M	$-43M	$-45M
EPS Avg	$-0.58	$-0.61	$-0.64	$-0.67	$-0.69	$-0.72
Low	$-0.58	$-0.61	$-0.64	$-0.67	$-0.69	$-0.72
High	$-0.58	$-0.61	$-0.64	$-0.67	$-0.69	$-0.72
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Jan 10, 2025Truist Financial

IGM Biosciences price target lowered to $2 from $12 at Truist

Target:$2.00

-4.3%from $2.09

Jan 10, 2025RBC Capital

IGM Biosciences downgraded to Sector Perform from Outperform at RBC Capital

Target:$1.50

-28.2%from $2.09

Dec 5, 2024BMO Capital

BMO Capital Starts IGM Biosciences (IGMS) at Outperform

Target:$21.00

+122.0%from $9.46

Oct 1, 2024RBC Capital

IGM Biosciences price target lowered to $17 from $20 at RBC Capital

Target:$17.00

+2.8%from $16.54

Oct 1, 2024Stifel Nicolaus

Stifel Reiterates Buy Rating on IGM Biosciences (IGMS)

Target:$25.00

+77.6%from $14.08

Oct 1, 2024Truist Financial

IGM Biosciences downgraded to Hold from Buy at Truist

Target:$12.00

-27.4%from $16.54

Aug 15, 2024Wedbush

IGM Biosciences price target raised to $25 from $20 at Wedbush

Target:$25.00

+186.7%from $8.72

Aug 14, 2024Morgan Stanley

Morgan Stanley Reiterates Overweight Rating on IGM Biosciences (IGMS)

Target:$12.00

+37.6%from $8.72

May 9, 2024RBC Capital

IGM Biosciences (IGMS) PT Lowered to $20 at RBC Capital

Target:$20.00

+114.1%from $9.34

Aug 23, 2022Truist Financial

Truist Securities Maintains Buy on IGM Biosciences, Lowers Price Target to $37

Target:$37.00

+89.5%from $19.53

Jun 20, 2022Robert W. Baird

IGM Biosciences (IGMS) Stock: $31 Target And Outperform Rating

Target:$31.00

+103.4%from $15.24

Mar 30, 2022Truist Financial

Why Did Truist Lower IGM Biosciences' Price Target?

Target:$74.00

+186.3%from $25.85

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance